<DOC>
	<DOCNO>NCT02441972</DOCNO>
	<brief_summary>The purpose study determine whether 18F-Al labeled RGD safety effective cancer diagnosis therapy response .</brief_summary>
	<brief_title>Clinic Study 18F-Al-NOTA-PRGD2 Cancer Diagnostics</brief_title>
	<detailed_description>Observe radiation dose healthy volunteer patient ; correlation integrin level tumor/metastases uptake .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma , Bronchogenic</mesh_term>
	<mesh_term>Soft Tissue Neoplasms</mesh_term>
	<criteria>1 . Volunteers patient age 18 yea ; 2 . The patient diagnose cancer suspect cancer ; 3 . It must fulfill ethical requirement subject sign informed consent . 1 . Pregnancy nurse mother ; 2 . Having drug alcohol dependence ; 3 . Hypersensitive active inactive ingredient study drug ; 4 . Having attend drug clinical trial within three month ; 5 . Cardiac functional insufficiency ; 6 . Hepatic renal function insufficiency ; 7 . Hypertensive patient serious complication ; 8 . Endangering safety life .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>